Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.77 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | GUSB | P08236 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309033 | 0.86 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL10275802 | 0.86 | CYSLTR2 (0.72) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL6175612 | 0.81 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL6175619 | 0.81 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL10275052 | 0.81 | PFKFB3 (0.74) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL10309012 | 0.81 | PFKFB3 (0.74) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL10275152 | 0.77 | KDM4E (0.61) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL10309042 | 0.77 | KDM4E (0.61) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL15548940 | 0.76 | ECE2 (0.72) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A | |
| SCHEMBL15548939 | 0.76 | ECE2 (0.72) | CYSLTR2CYSLTR1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552066-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552066-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2447248-A2 | Modified chalcone compounds as antimitotic agents | Arizona Biomedical Research Commission (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-09-02 | — | — | US | disclosed |
| US-7714025-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714025-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | TUBA1C, SARS1, TUBB1 | CYSLTR2 1564/4885CYSLTR1 1530/4885KDM4E 3737/4885 |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | TUBA1C, SARS1, TUBB1 | CYSLTR2 1505/4885CYSLTR1 1451/4885KDM4E 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.